TRIPOD Checklist: Prediction Model Development

Section/Topic	Item	Checklist Item	Page
Title and abstract			
Title	1	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	Page: 1 Line: 2
Abstract	2	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	Page: 3-4 Lines: 48-76
Introduction			
Background and objectives	3a	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	Page: 5-6 Lines: 83-106
	3b	Specify the objectives, including whether the study describes the development or validation of the model or both.	Page: 6 Lines: 108-111
Methods			
Source of data	4a	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable.	Page: 7 Lines: 113-115
	4b	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	Page: 7 Lines: 114-115
Participants	5a	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	Page: 7 Lines: 113-115
	5b	Describe eligibility criteria for participants.	Page: 7 Lines: 113-121
	5c	Give details of treatments received, if relevant.	Page: 7 Lines: 113-115
Outcome	6a	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	Page: 7 Lines: 124-131
	6b	Report any actions to blind assessment of the outcome to be predicted.	Page: Line: 113 (retrospective design)
Predictors	7a	Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.	Pages: 7-9 Lines: 115-121 133-180
	7b	Report any actions to blind assessment of predictors for the outcome and other predictors.	Page: 8 Lines: 150-156
Sample size	8	Explain how the study size was arrived at.	Page: 7 Lines: 113-116
Missing data	9	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	Page: 12 Line: 224
Statistical analysis methods	10a	Describe how predictors were handled in the analyses.	Page: 9-11 Lines: 181-215
	10b	Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.	Page: 8-9,10 Lines: 150-170 187-196
	10d	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	Page: 10 Lines: 187-188 1195-206
Risk groups	11	Provide details on how risk groups were created, if done.	not done
Results			
Participants	13a	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	Page: 12 Lines: 221-224
	13b	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	Page: 12 Lines: 221-227
Model development	14a	Specify the number of participants and outcome events in each analysis.	same answer as 14b
	14b	If done, report the unadjusted association between each candidate predictor and outcome.	Pages: 12-14 Lines: 223-278 (also refering to Tables)
Model specification	15a	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	Pages: 13 Line: 250 (refers to Table 2)
	15b	Explain how to the use the prediction model.	Page: 13 Lines: 247-250
Model performance	16	Report performance measures (with CIs) for the prediction model.	Page: 13-14 Lines: 250 265-267 274-278
Discussion			
Limitations	18	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	Page: 18 Lines: 349-370
Interpretation	19b	Give an overall interpretation of the results, considering objectives, limitations, and results from similar studies, and other relevant evidence.	Pages: 15,19 Lines: 279-285 375-382
Implications	20	Discuss the potential clinical use of the model and implications for future research.	Page: 19 Lines: 375-382
Other information			
Supplementary information	21	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	Page: 20 Line: 383
Funding	22	Give the source of funding and the role of the funders for the present study.	Page: 2 Lines: 40-41

We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document.

Article information: http://dx.doi.org/10.21037/jtd-20-2043.
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version.